Health Care & Life Sciences » Biotechnology | Myriad Genetics Inc.

Myriad Genetics Inc. | Balance Sheet

Fiscal year is July-June. All values USD Millions.
2014
2015
2016
2017
2018
Cash & Short Term Investments
186
145
159
151
181
Total Accounts Receivable
85
88
95
96
102
Inventories
24
25
38
42
34
Other Current Assets
27
26
22
13
9
Total Current Assets
322
284
315
302
326
Net Property, Plant & Equipment
35
67
58
51
43
Total Investments and Advances
89
46
80
49
31
Intangible Assets
374
370
423
808
774
Other Assets
-
-
5
-
-
Total Assets
824
766
944
1,308
1,226
Accounts Payable
23
21
21
22
26
Income Tax Payable
-
-
-
7
4
Other Current Liabilities
58
48
51
188
72
Total Current Liabilities
81
69
72
218
102
Long-Term Debt
-
-
-
99
9
Provision for Risks & Charges
24
31
30
44
40
Deferred Taxes
-
3
18
79
57
Other Liabilities
-
-
4
12
1
Total Liabilities
105
104
196
540
261
Common Equity (Total)
719
662
748
768
965
Total Shareholders' Equity
719
662
748
768
965
Total Equity
719
662
748
768
965
Liabilities & Shareholders' Equity
824
766
944
1,308
1,226
Accumulated Minority Interest
-
-
-
-
-

About Myriad Genetics

View Profile
Address
320 Wakara Way
Salt Lake City Utah 84108
United States
Employees -
Website http://www.myriad.com
Updated 07/08/2019
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through Diagnostics and Other segments. The Diagnostics segment engages in the provision of testing and collaborative development of testing that is designed to asses a risk of developing a disease later in life of an individual.